A prospective, multi-center randomized clinical trial evaluated the effectiveness of OrthoCor Pulsed Shortwave Therapy (PST) as a non-pharmacologic option for joint and soft tissue pain relief. In this study, patients using OrthoCor PST experienced substantial reductions in both pain and reliance on medication compared to standard care.
Key Findings
- OrthoCor PST reduced mean by 42%—3x the reduction than seen with standard of care (SOC) (p < 0.0001)
- Daily pharmacological use dropped by 55%—4x the reduction seen with SOC ( p < 0.0001)
- Among SOC patients who crossed over to OrthoCor PST medication use dropped by 63%.
Study Design
The randomized controlled trial enrolled 120 patients across multiple sites. Participants with joint or soft tissue pain were assigned either to SOC or at-home PST therapy for 14 days where they traced daily pain levels and pharmacological use. SOC patients were later given the option to PST therapy for an additional 16 days.
Results
Outcomes were analyzed from 91 patients with complete data. Those using PST therapy showed over a 3x pain reduction and a 55% decrease in medication use, compared to 12% in SOC. Notably, patients in the crossover subgroup achieved an additional 18% decrease in pain and a 63% reduction in pharmacologic use after starting PST.
OrthoCor PST therapy demonstrated strong clinical effectiveness in reducing both pain and the need for medication, with no reported safety concerns.
